Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05205967 · ClinicalTrials.gov registry record

REFLECTION: A Clinical Practice Learning Program for Galleri®

A clinical trial of Cancer and Early Detection of Cancer, sponsored by GRAIL.

Active
Registry status
14,633
Enrollment target
16
Study locations

NCT05205967: Active study of Cancer and Early Detection of Cancer, sponsored by GRAIL.

NCT05205967 is a study of Cancer and Early Detection of Cancer that is active but no longer recruiting, run by GRAIL. The registered enrollment target is 14,633 participants, above the 3,467-participant average among 615 other Cancer trials with a reported enrollment target (322% higher). The trial reports 16 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05205967, a study of Cancer and Early Detection of Cancer, is active but no longer recruiting, sponsored by GRAIL.

ACTIVE NOT RECRUITING
Registry status
14,633 participants
Enrollment target
16
Study locations

Study Summary

REFLECTION is a multi-center, prospective, non-interventional, cohort study that will enroll approximately 14,000 individuals who have opted to be screened with Galleri®, a blood-based, multi-cancer early detection (MCED) test in routine clinical settings. The purpose of the study is to understand the real-world experience of Galleri® in clinical settings.

Interventions

  • OTHER SOC
  • OTHER MCED

Study Locations (16)

California

  • Providence - Burbank
  • Providence, St. Jude - Fullerton
  • Providence, Mission - Mission Viejo
  • Providence, Orange County - Orange

Florida

  • VA Miami Health Care System - Miami
  • James A. Haley Veterans Hospital (VA Tampa) - Tampa

Pennsylvania

  • VA Pittsburgh Healthcare System - Pittsburgh
  • VA Wilkes Barre Medical Center - Wilkes-Barre

South Carolina

  • Carolina Blood and Cancer Care Associate - Lancaster
  • Carolina Blood and Cancer Care Associates - Rock Hill

Arizona

  • Vincere Cancer Center - Scottsdale

Louisiana

  • Southeast Louisiana Veterans Health Care System (SLVHCS) (VA New Orleans) - New Orleans

Massachusetts

  • Boston VA Research Institute (VA Boston) - Boston

Oregon

  • Providence - Portland

Trial Details

FieldValue
Enrollment Target 14,633 participants
Start Date 2021-08-23
Est. Completion 2026-10-30
GRAIL

5 total trials

What the registry record for NCT05205967 still lists

NCT05205967 is an observational study that tracks outcomes without assigning an intervention. Its 14,633 participants enrollment target places it among the larger protocols in the corpus, above the 3,467-participant average among 615 other Cancer trials with a reported enrollment target (322% higher).

The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which SOC is the first listed.

NCT05205967 lists 16 locations in 10 states (California, Florida, Pennsylvania).

Frequently Asked Questions

What is clinical trial NCT05205967 about?

NCT05205967 is a clinical study titled "REFLECTION: A Clinical Practice Learning Program for Galleri®". REFLECTION is a multi-center, prospective, non-interventional, cohort study that will enroll approximately 14,000 individuals who have opted to be screened with Galleri®, a blood-based, multi-cancer early detection (MCED) test in routine clinical settings. The purpose of the study is to understand t...

What is the current status of trial NCT05205967?

This trial is currently active not recruiting. The enrollment target is 14,633 participants. The study started on 2021-08-23. Estimated completion is 2026-10-30.

What conditions does trial NCT05205967 study?

This clinical trial studies the following conditions: Cancer, Early Detection of Cancer.

What interventions are being tested in trial NCT05205967?

The interventions under investigation include: SOC (OTHER), MCED (OTHER).

Who is sponsoring clinical trial NCT05205967?

This trial is sponsored by GRAIL, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05205967 being conducted?

This trial has 16 study locations across Arizona, California, Florida, Louisiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05205967's enrollment target sits among peer trials

14,633 22nd of 615 higher than 594 of 615 other Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05359016 · 14,600 participants · NA

    Evaluating Innovative Technologies and Approaches to Addressing Cervical Cancer in Gaza and Maputo Cidade Provinces in Mozambique

  • NCT06849869 · 14,820 participants · NA

    Collaborative Care Model for Perinatal Wellness Support Services - Population-Level Equity-Centered Systems Change

  • NCT05591066 · 14,400 participants · NA

    The Patient and Family Centered I-PASS LISTEN Study: Language, Inclusion, Safety, and Teamwork for Equity Now

  • NCT00857922 · 15,000 participants

    Neurosciences Research Repository

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05205967, the US trial registry maintained by the National Library of Medicine. NCT05205967 (large enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.